dc.contributor.author
Furian, Lucrezia
dc.contributor.author
Crespo Barrio, Marta
dc.contributor.author
Naesens, Maarten
dc.date.accessioned
2026-02-14T19:05:31Z
dc.date.available
2026-02-14T19:05:31Z
dc.date.issued
2026-02-13T14:04:46Z
dc.date.issued
2026-02-13T14:04:46Z
dc.date.issued
2026-02-13T14:04:46Z
dc.identifier
Furian L, Heemann U, Bengtsson M, Bestard O, Binet I, Bohmig GA, Boletis J, Briggs D, Claas FHJ, Couzi L, Cozzi E, Crespo M, De Vries APJ, Diekmann F, Durlik M, Glotz D, Helantera I, Jackson A, Jordan SC, Kuypers D, Lefaucheur C, Legendre C, Lorant T, Maggiore U, Mamode N, Marinaki S, Massart A, Muller T, Oberbauer R, Renders L, Roelen D, Taupin JL, Viklický O, Vittoraki A, de Weerd AE, Naesens M. Desensitization with imlifidase for HLA-incompatible deceased donor kidney transplantation: a delphi international expert consensus. Transpl Int. 2025 Jan 6;37:13886. DOI: 10.3389/ti.2024.13886
dc.identifier
https://hdl.handle.net/10230/72541
dc.identifier
http://dx.doi.org/10.3389/ti.2024.13886
dc.identifier.uri
http://hdl.handle.net/10230/72541
dc.description.abstract
Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor¿recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Transplant International. 2024;37:13886
dc.rights
© 2025 Furian, Heemann, Bengtsson, Bestard, Binet, Böhmig, Boletis, Briggs, Claas, Couzi, Cozzi, Crespo, De Vries, Diekmann, Durlik, Glotz, Helantera, Jackson, Jordan, Kuypers, Lefaucheur, Legendre, Lorant, Maggiore, Mamode, Marinaki, Massart, Müller, Oberbauer, Renders, Roelen, Taupin, Viklický, Vittoraki, de Weerd and Naesens. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. http://creativecommons.org/licenses/by/4.0/
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
HLA incompatible
dc.subject
Desensitization
dc.subject
Kidney transplantation
dc.title
Desensitization with imlifidase for HLA-incompatible deceased donor kidney transplantation: a delphi international expert consensus
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
